The pharmacokinetics (PK) of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP), the active anabolites of tenofovir disoproxil fumarate (TDF), and emtricitabine (FTC) in blood, genital, and rectal compartments was determined in HIV-positive and seronegative adults who undertook a 60-day intensive PK study of daily TDF/FTC (plus efavirenz in HIV positives). Lymphocyte cell sorting, genital, and rectal sampling occurred once per subject, at staggered visits. Among 19 HIV-positive (3 female) and 21 seronegative (10 female) adults, TFV-DP in peripheral blood mononuclear cells (PBMC) accumulated 8.6-fold [95% confidence interval (CI): 7.2–10] from first-dose to steady-state concentration (Css) versus 1.7-fold (95% CI: 1.5–1.9) for FTC-TP. Css was reached in ∼11 and 3 days, respectively. Css values were similar between HIV-negative and HIV-positive individuals. Css TFV-DP in rectal mononuclear cells (1,450 fmol/106 cells, 898–2,340) was achieved in 5 days and was >10 times higher than PBMC (95 fmol/106 cells, 85–106), seminal cells (22 fmol/106 cells, 6–79), and cervical cells (111 fmol/106 cells, 64–194). FTC-TP Css was highest in PBMC (5.7 pmol/106 cells, 5.2–6.1) and cervical cells (7 pmol/106 cells, 2–19) versus rectal (0.8 pmol/106 cells, 0.6–1.1) and seminal cells (0.3 pmol/106 cells, 0.2–0.5). Genital drug concentrations on days 1–7 overlapped with estimated Css, but accumulation characteristics were based on limited data. TFV-DP and FTC-TP in cell sorted samples were highest and achieved most rapidly in CD14+ compared with CD4+, CD8+, and CD19+ cells. Together, these findings demonstrate cell-type and tissue-dependent cellular pharmacology, preferential accumulation of TFV-DP in rectal mononuclear cells, and rapid distribution into rectal and genital compartments.
Get full access to this article
View all access options for this article.
References
1.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf accessed January1, 2016.
2.
FDA: Press announcements – FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at www.fda.gov/newsevents/newsroom/pressannouncements/ucm312210.htm, accessed November25, 2014.
3.
World Health Organization: Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV. World Health Organization, Geneva, 2015.
4.
Centers for Disease Control and Prevention. Available at www.cdc.gov/hiv/pdf/prepguidelines2014.pdf accessed December12, 2015.
5.
GrantRM, LamaJR, AndersonPL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med, 2010; 363:2587–2599.
6.
BaetenJM, DonnellD, NdaseP, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med, 2012; 367:399–410.
7.
ThigpenMC, KebaabetswePM, PaxtonLA, et al.: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med, 2012; 367:423–434.
8.
Van DammeL, CorneliA, AhmedK, et al.: Preexposure prophylaxis for HIV infection among African women. N Engl J Med, 2012; 367:411–422.
9.
MarrazzoJM, RamjeeG, RichardsonBA, et al.: Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med, 2015; 372:509–518.
10.
SpinnerCD, BoeseckeC, ZinkA, et al.: HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection, 2016; 44:151–158.
11.
HendrixCW: Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design. Cell, 2013; 155:515–518.
12.
CottrellML, SrinivasN, KashubaAD: Pharmacokinetics of antiretrovirals in mucosal tissue. Expert Opin Drug Metab Toxicol, 2015; 11:893–905.
13.
PattersonKB, PrinceHA, KraftE, et al.: Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med, 2011; 3:112re4.
14.
CihlarT, RayAS: Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 Years after zidovudine. Antiviral Res, 2010; 85:39–58.
15.
AndersonPL, KiserJJ, GardnerEM, RowerJE, MeditzA, GrantRM: Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother, 2011; 66:240–250.
16.
MolinaJM, CapitantC, SpireB, et al.: On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med, 2015; 373:2237–2246.
17.
LouissaintNA, CaoYJ, SkipperPL, et al.: Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res Hum Retroviruses, 2013; 29:1443–1450.
18.
BushmanLR, KiserJJ, RowerJE, et al.: Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal, 2011; 56:390–401.
19.
SeifertSM, GliddenDV, MeditzAL, et al.: Dose-response for starting and stopping HIV pre-exposure prophylaxis (PrEP) for MSM. Clin Infect Dis, 2015; 60:804–810.
20.
DelahuntyT, BushmanL, RobbinsB, FletcherCV: The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci, 2009; 877:1907–1914.
21.
KwanK, BohidarN, HwangS: Estimation of an effective half-life. In: Pharmacokinetics: A Modern View (BenetLZ, LevyG, FerraioloB, eds.) Plenum Press, New York, NY, 1984, pp. 147–162.
HendrixCW, ChenBA, GudderaV, et al.: MTN-001: Randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One, 2013; 8:e55013.
24.
PruvostA, NegredoE, BenechH, et al.: Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 2005; 49:1907–1914.
25.
HawkinsT, VeikleyW, St ClaireRL3rd, GuyerB, ClarkN, KearneyBP: Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr, 2005; 39:406–411.
26.
HendrixCW, AndradeA, BumpusNN, et al.: Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses, 2016; 32:32–43.
27.
MadrasiK, BurnsRN, HendrixCW, FosslerMJ, ChaturvedulaA: Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism. CPT Pharmacometrics Syst Pharmacol, 2014; 3:e147.
28.
BMS: SUSTIVA® (efavirenz) package insert. Available at http://packageinserts.bms.com/pi/pi_sustiva.pdf, accessed April17, 2016.
29.
GrantRM, AndersonPL, McMahanV, et al.: Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: A cohort study. Lancet Infect Dis, 2014; 14:820–829.
30.
LiuA, CohenS, VittinghoffE, et al.: Adherence, sexual behavior and HIV/STI incidence among men who have sex with men (MSM) and transgender women (TGW) in the US PrEP demonstration (Demo) project. In: Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, BC, 2015. Abstract TUAC0202.
31.
McCormackS, DunnDT, DesaiM, et al.: Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet, 2016; 387:53–60.
32.
LiuA, CohenS, VittinghoffE, et al.: Preexposure prophylaxis for human immunodeficiency virus infected integrated with municipal- and community-based sexual health services. JAMA Intern Med, 2016; 176:75–84.
33.
HosekS, RudyB, LandovitzR, et al.: ATN 110: An HIV PrEP demonstration project and safety study for young men who have sex with men in the United States. In: IAS 2015, 8th IAS Conference on HIV Pathogenesis Treatment and Prevention, Vancouver, BC, 2015.
34.
AndersonPL, Garcia-LermaJG, HeneineW: Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS, 2016; 11:94–101.
35.
CottrellML, YangKH, PrinceHM, et al.: A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis, 2016; 214:55–64.
36.
BaetenJM, DonnellD, MugoNR, et al.: Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: An update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis, 2014; 14:1055–1064.
37.
FonnerVA, DalglishSL, KennedyCE, et al.: Effectiveness and safety of oral HIV pre-exposure prophylaxis (PrEP) for all populations: A systematic review and meta-analysis. AIDS, 2016; 30:1973–1983.
38.
BekkerL, HughesJ, AmicoK, et al.: HPTN 067/ADAPT background and methods and Cape Town results. In: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention, Vancouver, BC, July18–22, 2015.
39.
MannheimerS, Hirsch-MovermanY, LoquereA, et al.: Feasibility of intermittent PrEP among US MSM: Data from the Harlem Site. In: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention, Vancouver, BC, July18–22, 2015.
40.
HoltzT, ChitwarakornA, CurlinM, et al.: A comparison of daily and nondaily preexposure prophylaxis dosing in Thai men who have sex with men, Bangkok. In: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention, Vancouver, BC, July18–22, 2015.
41.
RowerJE, MeditzA, GardnerEM, et al.: Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother, 2012; 56:3011–3019.
42.
ChapmanEH, KurecAS, DaveyFR: Cell volumes of normal and malignant mononuclear cells. J Clin Pathol, 1981; 34:1083–1090.
43.
TuttleDL, HarrisonJK, AndersC, SleasmanJW, GoodenowMM: Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol, 1998; 72:4962–4969.
44.
ShenZ, FaheyJV, BodwellJE, Rodriguez-GarciaM, KashubaAD, WiraCR: Sex hormones regulate tenofovir-diphosphate in female reproductive tract cells in culture. PLoS One, 2014; 9:e100863.
45.
Barditch-CrovoP, DeeksSG, CollierA, et al.: Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother, 2001; 45:2733–2739.
46.
Garcia-LermaJG, CongME, MitchellJ, et al.: Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med, 2010; 2:14ra4.
47.
YangKH, HendrixC, BumpusN, et al.: A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One, 2014; 9:e106196.
48.
Gilead: TRUVADA® package insert. Available at http://start.truvada.com/hcp#, accessed November25, 2014.
49.
LadeJ, ToE, HendrixC, BumpusN: Discovery of genetic variants of the kinases that activate tenofovir in a compartment-specific manner – EBioMedicine. EBioMedicine, 2015; 2:1145–1152.
50.
HuM, PatelSK, ZhouT, RohanLC: Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. J Control Release, 2015; 219:681–696.
51.
GiraudC, ManceauS, DeclevesX, et al.: Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes. J Clin Pharmacol, 2010; 50:226–230.
52.
FletcherCV, StaskusK, WietgrefeSW, et al.: Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A, 2014; 111:2307–2312.
53.
DumondJB, YehRF, PattersonKB, et al.: Antiretroviral drug exposure in the female genital tract: Implications for oral pre- and post-exposure prophylaxis. AIDS, 2007; 21:1899–1907.
54.
VourvahisM, TappouniHL, PattersonKB, et al.: The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr, 2008; 47:329–333.
55.
LoweSH, van LeeuwenE, DrosteJA, et al.: Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen. Ther Drug Monit, 2007; 29:566–570.
56.
GhosnJ, ChaixML, PeytavinG, et al.: Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS, 2004; 18:1958–1961.
57.
SchwartzJL, RountreeW, KashubaAD, et al.: A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One, 2011; 6:e25974.
58.
SahinS, BenetLZ: The operational multiple dosing half-life: A key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res, 2008; 25:2869–2877.
59.
Salmon-CeronD, LassalleR, PruvostA, et al.: Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: A CORIST-ANRS HC1 trial. Clin Infect Dis, 2003; 36:1295–1304.
60.
LahiriCD, TaoS, JiangY, et al.: Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients. AIDS, 2015; 29:1113–1115.
61.
WangLH, BegleyJ, St ClaireRL3rd, HarrisJ, WakefordC, RousseauFS: Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses, 2004; 20:1173–1182.
62.
DuwalS, SchutteC, von KleistM: Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One, 2012; 7:e40382.
63.
ChenJ, FlexnerC, LibermanRG, et al.: Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr, 2012; 61:593–599.
64.
BenechH, TheodoroF, HerbetA, et al.: Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal Biochem, 2004; 330:172–174.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
